Order of abstracts:
- Armstrong et al – VICTORIA trial – Vericiguat shows beneficial effects in very high-risk HF population
- Bonaca et al – VOYAGER-PAD trial – Rivaroxaban and aspirin effective and safe for PAD patients
- Pereira et al – TAILOR-PCI trial – TAILOR-PCI misses endpoint but still provides valuable insights
- Leon et al – PARTNER 3 trial – 2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
- Agnelli et al – CARAVAGGIO trial – Apixaban offers new perspective for cancer patients in need of anticoagulation
- Samama et al – Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Posted on
Previous Article
« ACC.20/WCC Highlights Podcast Part 2 of 3 Next Article
No role for sodium nitrite in out-of-hospital cardiac arrest »
« ACC.20/WCC Highlights Podcast Part 2 of 3 Next Article
No role for sodium nitrite in out-of-hospital cardiac arrest »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 8, 2020
TAVR model reveals differences in hospital outcomes
September 8, 2020
PCI and CABG are equal in left main CAD
September 8, 2020
Real-world evidence for MitraClip
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy